← Amneal Pharmaceuticals, Inc. (AMRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Amneal Pharmaceuticals, Inc. (AMRX)
Pharmaceutical Preparations · market cap $6.1B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
9
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Amneal Pharmaceuticals (AMRX) is one of the largest U.S. generic drug manufacturers, generating $3.0B in 2025 revenue across a broad generics and specialty portfolio. The company carries $2.38B in net debt against $197.7M in cash (~22 months runway), and its pipeline is composed almost entirely of Phase 3 generic/505(b)(2) candidates rather than novel therapeutics. The next public event is an earnings release on 2026-08-04.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Phenazopyridine Hydrochloride Tables, USP 200 mg | Phase 3 | Uncomplicated Urinary Tract Infections |
| Testosterone Topical Gel, 1.62% Metered Pump | Phase 3 | Primary Hypogonadism |
| Estradiol Vaginal Tablets 10 mcg | Phase 3 | Atrophic Vaginitis Due to Menopause |
| Asenapine Sublingual Tablets 10 mg | Phase 3 | Schizophrenia |
| Imatinib Mesylate Tablets, 400 mg | Phase 3 | Chronic Myeloid Leukemia |
| Phenazopyridine Hydrochloride | Phase 3 | Pain |
| Mometasone Furoate Nasal Spray, 50 mcg | Phase 3 | Seasonal Allergic Rhinitis |
| Test - Bimatoprost 0.01% Ophthalmic Solution | Phase 3 | Glaucoma, Open-Angle |
| Diclofenac Sodium Topical Gel, 1% | Phase 3 | Osteoarthritis |
Price & technical context
3-month
+17.0%
6-month
+57.9%
12-month
+100.5%
52-wk range
$9.72–$20.50
vs 50-day MA
+9.8%
vs 200-day MA
+34.1%
Realized vol
35.4%
Max drawdown
-24.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AMRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.